Information updates

Updated ASCIA article on oral immunotherapy (OIT) for food allergy

24 May 2019

ASCIA has updated its information on oral immunotherapy (OIT) for food allergy to include information from a meta-analysis (a method to combine data from multiple studies) of 12 OIT trials.  This meta-analysis was published in the Lancet journal in April 2019 and is the most comprehensive and rigorous review of OIT for peanut allergy to date. OIT for food allergy is an emerging experimental treatment, and its benefits and harms are still being studied in clinical trials globally.  The updated ASCIA article is available at:

www.allergy.org.au/patients/allergy-treatment/oral-immunotherapy-for-food-allergy

Recent Lancet publication is a comprehensive review of OIT for peanut allergy

A meta-analysis that combined data from 12 OIT trials was published in the Lancet journal in April 2019. This is the most comprehensive and rigorous review of OIT for peanut allergy to date. It reviewed the effectiveness and safety of OIT for peanut versus placebo (in OIT study but in the group that was not given peanut) or peanut avoidance (patients not in OIT study).

Results showed that whilst OIT can achieve the goal of desensitisation for many people, those receiving OIT had more frequent allergic reactions, including anaphylaxis. They also required more frequent treatment with adrenaline (epinephrine) autoinjectors (such as EpiPen) than those who avoided peanut and did not receive OIT.

The Lancet publication supports the need for improved food allergy treatment approaches with an enhanced safety profile and trials focused on patient-important outcomes. ASCIA also supports this approach.

The abstract of the Lancet publication is available at:

www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30420-9/fulltext

Mod ASCIA Member
Donate to AIFA
go to NAS website
Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:

About ASCIA

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links

About ASCIA

ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Accreditiation

healthdirect

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.